BERKELEY, CALIFORNIA (US), June 6, 2012 — For decades, medical experts have believed that the blocked arteries leading to heart attack and stroke are the result of a deadly combination of cholesterol, fat and the smooth muscle cells within a blood vessel's walls
You are here
Coverage of the latest news and updates from the field of stem cells.
Several newspapers and scientific web sites were reporting on June 8 that a team of scientists at Yokohama City University, led by Dr. Hideki Taniguchi, successfully transplanted induced pluripotent stem (iPS) cells into the body of a mouse where they began to grow into a human liver.
Multipotent vascular stem cells &mdash a previously unknown type of stem cell &mdash should be the focus in the search for new treatments, the scientists report in the June 6 edition of Nature Communications.
Prior to the study, which is published in the current edition of PLoS ONE, hematopoietic stem cells were thought to have no other option when they went into quiescence and that it was brought on by a lack of nutrients or stimulation.
Osteonecrosis occurs when the patient's bone tissue dies after a loss of blood supply to the area. If the bone involved is near a joint, it can cause the joint surface to collapse. In most cases, the disease first attacks people in their late 30s and 40s.
The U.S. National Heart, Lung and Blood Institute reports that in the United States alone, about 5.8 million people suffer from heart failure.
Their work, published May 4 in Cell Stem Cell, sets the stage for future human clinical trials.
"Despite the huge potential of stem cells for therapeutic use, very few people have actually investigated their basic biology," said study senior researcher Mohanish Deshmukh, Ph.D., of the University of North Carolina at Chapel Hill (US).
Scientists at Cincinnati Children's Hospital Medical Center (US) and the Ulm University Medicine in Germany reported their findings online May 3 in Cell Stem Cell.
The facility will produce GIBCO® cell culture products used for biological drug research, development and production. The company expects to break ground at the site in 2013 and to ship product from the facility beginning in 2014.